MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Home・Aandelen Lijst・Celsion Corp

Celsion Corp

Gesloten

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+474.53% upside

Celsion Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 apr 2026, 23:17 UTC

Winsten

Samsung Forecasts Record First-Quarter Operating Profit

6 apr 2026, 23:00 UTC

Populaire aandelen

Stocks to Watch: Health Insurers, Mawson, Owlet

6 apr 2026, 22:13 UTC

Belangrijke Marktbewegers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 apr 2026, 21:46 UTC

Acquisities, Fusies, Overnames

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 apr 2026, 17:09 UTC

Belangrijke Marktbewegers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 apr 2026, 16:56 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 apr 2026, 14:47 UTC

Belangrijke Marktbewegers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 apr 2026, 23:58 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 apr 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 apr 2026, 23:36 UTC

Marktinformatie

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 apr 2026, 23:15 UTC

Marktinformatie

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 apr 2026, 22:52 UTC

Marktinformatie

Global Equities Roundup: Market Talk

6 apr 2026, 22:52 UTC

Marktinformatie

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 apr 2026, 22:14 UTC

Marktinformatie

Correction to Live Cattle Futures Article

6 apr 2026, 20:56 UTC

Marktinformatie

Mexican Private Consumption Fell in January -- Market Talk

6 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

6 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

6 apr 2026, 19:58 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

6 apr 2026, 19:58 UTC

Marktinformatie

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 apr 2026, 19:11 UTC

Marktinformatie

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 apr 2026, 19:06 UTC

Marktinformatie

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 apr 2026, 19:03 UTC

Marktinformatie

Global Energy Roundup: Market Talk

6 apr 2026, 19:03 UTC

Marktinformatie

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 apr 2026, 18:36 UTC

Acquisities, Fusies, Overnames

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 17:59 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 apr 2026, 17:13 UTC

Acquisities, Fusies, Overnames

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 16:33 UTC

Marktinformatie

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 apr 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

6 apr 2026, 14:59 UTC

Winsten

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Vergelijking

Prijswijziging

Celsion Corp Prognose

Koersdoel

By TipRanks

474.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.5 USD 474.53%

Hoogste 25 USD

Laagste 12 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celsion Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Celsion Corp - Dist in de afgelopen 3 maanden.

Financieel

Over Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.